NPPA caps trade margins at 30% for 137 non-scheduled anti-cancer drugs; revised prices effective November 9, 2026
Why this matters
Cancer medicines can impose catastrophic costs because some newer drugs are outside routine price control and carry very high distribution mark-ups. The measure tests whether India can improve access through targeted price regulation without causing shortages or weakening pharmaceutical supply.
In plain words
This decision sits at the intersection of public health and market regulation. The National Pharmaceutical Pricing Authority, or NPPA, has brought 137 identified non-scheduled anti-cancer drugs under Trade Margin Rationalisation. These medicines include immunotherapy and targeted treatments such as pembrolizumab, durvalumab and osimertinib, along with denosumab, pegfilgrastim and bevacizumab. Their revised prices will apply from November 9, 2026.
The basic mechanism is simple: the government is not fixing the manufacturing cost of every medicine. It is limiting how much can be added by the distribution and retail chain after the medicine leaves the manufacturer. The trade margin is capped at 30% of the Maximum Retail Price, excluding Goods and Services Tax. In practical terms, this corresponds to a mark-up of about 42.86% over the price to the stockist or distributor. If the existing price is already lower than the calculated price, the lower price must continue.
Think of the medicine price as a ladder: the manufacturer sets the first rung, and wholesalers, hospitals or retailers add later rungs. The policy cuts down unusually high later rungs while asking manufacturers to maintain production and supply. The government expects maximum retail prices to fall by up to 70%, although the actual reduction will differ across medicines. Manufacturers must submit revised prices within seven days, display them publicly and ensure hospitals charge the revised prices.
Key facts
- The National Pharmaceutical Pricing Authority covered 137 identified non-scheduled anti-cancer drugs under Trade Margin Rationalisation.
- The trade margin has been capped at 30% over the relevant first-point-of-sale price, excluding GST.
- The revised prices are scheduled to come into effect on November 9, 2026.
- The intervention may reduce MRPs by up to 70%, depending on existing price structures.
- The measure expands the 2019 pilot, which covered 42 anti-cancer drugs and reportedly reduced prices of 526 brands by up to 90%.
How we got here
India regulates some medicines through scheduled formulations whose prices are controlled under the Drugs (Prices Control) Order, 2013. Non-scheduled medicines are not automatically subject to the same ceiling-price method, but Paragraph 19 of the Order allows the National Pharmaceutical Pricing Authority to intervene in public interest when excessive pricing or trade margins threaten affordability.
The present action expands a 2019 pilot covering 42 anti-cancer drugs. According to the Department of Pharmaceuticals, that exercise reduced the maximum retail prices of 526 brands by up to 90%. The new list was recommended by an Expert Committee under the Directorate General of Health Services, comprising oncologists, medical specialists, hospital experts and government officers.
The 2026 notification responds to evidence that non-scheduled anti-cancer medicines had an average trade mark-up of about 170%, with some cases reaching 700%. Cancer medicines have an annual market of around ₹12,500 crore, but scheduled medicines account for only about ₹2,250 crore. The current intervention therefore targets a large unregulated segment while preserving the lower existing price wherever it is already cheaper.
The bigger picture
Economic
Price discovery and distribution margins
The policy addresses a market in which patients often cannot compare prices because medicines may be prescribed, dispensed and administered through hospitals. Indian Express reported an average trade mark-up of approximately 170% for the covered non-scheduled medicines, with some mark-ups reaching 700%. The 30% cap is calculated on maximum retail price excluding Goods and Services Tax and is equivalent to a 42.86% mark-up over the price to the stockist or distributor. The measure can transfer part of the surplus from intermediaries to patients, but implementation must prevent hidden charges or substitution with another expensive brand.
The policy targets excessive distribution margins rather than imposing a universal manufacturing-price ceiling.
Social
Financial protection and health equity
Cancer treatment can push households into debt, particularly when high-cost medicines must be purchased repeatedly. The Indian Express cited Tata Memorial Hospital research showing that only 1.6% of patients needing patented targeted therapy actually received it, with cost the major barrier. Lower prices may improve adherence and widen access, but price reduction alone cannot solve shortages, diagnostic delay, unequal oncology facilities or travel costs. Benefits will be strongest if hospitals transparently display prices and patients can verify them through the Pharma Sahi Daam application and the NPPA website.
Affordable medicines improve access only when diagnosis, hospitals, information and supply are also available.
Other angle
Affordability versus uninterrupted supply
The notification requires manufacturers to maintain present production levels and seek prior permission before reducing average monthly output; discontinuation must also be reported. This condition recognises a central risk of price regulation: if margins fall sharply, a company may reduce supply or withdraw a low-volume formulation. Hospitals are especially important because many anti-cancer medicines are sold directly to medical institutions. State Drug Controllers must monitor manufacturers, dealers, retailers, hospitals and medical institutions, making enforcement capacity as important as the price formula.
A lower printed price helps only if the medicine remains available at the point of treatment.
Constitutional
Public interest and regulatory power
The intervention illustrates the State's responsibility to make healthcare more accessible while regulating private economic activity in the public interest. Paragraph 19 of the Drugs (Prices Control) Order, 2013 provides the specific regulatory route used by the NPPA. The policy must still be transparent, evidence-based and procedurally fair because it affects manufacturer revenues and commercial decisions. A defensible framework therefore requires clear calculations, reasons for inclusion, an opportunity to correct data and accessible grievance redressal, alongside protection against overcharging.
Price control is strongest when public-interest regulation is paired with transparent procedure and accountability.
Ethical
Innovation, patents and distributive justice
Several included medicines are patented, meaning competition from equivalent products may be limited. Trade-margin control can reduce avoidable mark-ups, but it cannot automatically make a costly patented therapy affordable if the underlying price is high. Patient assistance programmes may also complicate price calculations when medicines are supplied free under conditional schemes. Ethical policy must balance rewards for research and reliable supply with the principle that ability to pay should not determine access to life-saving treatment. Public procurement and insurance support may therefore be needed alongside margin regulation.
The reform corrects one layer of cost, but justice may require action on patents, procurement and financial protection too.
The big debate
Will capping trade margins on 137 non-scheduled anti-cancer drugs substantially improve cancer access without harming medicine availability?
For
- It directly targets excessive intermediary mark-ups and can reduce maximum retail prices by up to 70%.
- The 2019 pilot reportedly reduced prices of 526 brands by up to 90%, creating a tested administrative precedent.
- Mandatory production and disclosure requirements reduce the risk that lower prices will produce artificial shortages.
- Transparent hospital pricing can improve patient bargaining power and reduce information asymmetry.
Against
- Margin control cannot by itself reduce the high research, patent, import or manufacturing costs of newer medicines.
- Sharp reductions may weaken incentives for distribution, especially in low-volume or geographically difficult markets.
- Hospitals may shift costs into administration, infusion, consultation or bundled charges unless billing is monitored.
- Weak enforcement by State Drug Controllers could create a gap between notified prices and actual patient payments.
On balance. The policy is justified because the reported mark-ups are unusually high and cancer patients have weak bargaining power. However, it is not a complete affordability solution. Success depends on monitoring availability, hospital billing and patient outcomes, while combining margin regulation with public procurement, insurance coverage, competition and stronger oncology infrastructure.
For or against?
“Mandatory production and disclosure requirements reduce the risk that lower prices will produce artificial shortages.”
For or against?
“Weak enforcement by State Drug Controllers could create a gap between notified prices and actual patient payments.”
Answer it in Mains
GS2
Healthcare affordability is a prerequisite for substantive equality. Discuss in the context of regulating prices of anti-cancer medicines.
Approach. Begin with catastrophic health expenditure and unequal access to cancer care. Analyse price regulation, hospital transparency, insurance, public procurement and rural oncology gaps. Conclude that affordability requires both lower prices and effective service delivery.
Worth quoting. Tata Memorial Hospital finding cited by Indian Express that only 1.6% of patients needing patented targeted therapy received it; National Health Policy, 2017.
GS3
Examine the role of the National Pharmaceutical Pricing Authority in balancing public interest with pharmaceutical-sector viability.
Approach. Define trade-margin regulation and distinguish it from complete price fixation. Discuss Paragraph 19 of the Drugs (Prices Control) Order, 2013, consumer welfare, innovation, supply continuity and enforcement. Conclude with transparent, data-driven periodic review.
Worth quoting. Paragraph 19 of the Drugs (Prices Control) Order, 2013; NPPA's 2019 anti-cancer trade-margin pilot and 2026 notification.
Essay
High medicine prices reflect both market failure and gaps in public health financing. Discuss with reference to cancer treatment in India.
Approach. Use the medicine-price ladder as the introduction. Build the essay through mark-ups, patents, information asymmetry, household financial distress, insurance and public procurement. End by linking affordability with dignity, prevention, early diagnosis and universal health coverage.
Worth quoting. 2026 reported cancer-drug market size of about ₹12,500 crore, of which scheduled drugs account for about ₹2,250 crore; 2019 pilot savings reported by NPPA.
GS3
How can India ensure that pharmaceutical price regulation does not result in shortages or reduced innovation?
Approach. Present the access-versus-incentive tension. Examine production-maintenance requirements, monitoring, competition, quality-assured alternatives, procurement and targeted support for genuine research costs. Conclude that predictable regulation is superior to abrupt, opaque intervention.
Worth quoting. The 2026 notification's requirement to maintain current production and report intended reductions or discontinuation; World Health Organization Fair Pricing of Medicines report, 2017.
Prelims quick-fire
- Body/Institution. The National Pharmaceutical Pricing Authority is under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. NPPA is not an autonomous health ministry body; it functions under the Department of Pharmaceuticals.
- Term. Trade Margin Rationalisation covers 137 identified non-scheduled anti-cancer drugs under Paragraph 19 of the Drugs (Prices Control) Order, 2013. The policy regulates excessive margins; it is not the same as placing every medicine under scheduled price ceilings.
- Data. The revised prices for the 137 covered medicines become effective on November 9, 2026, according to the October 17, 2026 notification. Do not confuse the notification date with the implementation date.
- Term. The 30% trade margin is calculated on maximum retail price excluding Goods and Services Tax; it equals a 42.86% mark-up over stockist price. Margin on selling price and mark-up on cost are different mathematical concepts.
- Data. The 2019 pilot covered 42 anti-cancer drugs and reportedly reduced maximum retail prices of 526 brands by up to 90%. The pilot's 42 drugs and the present 137 drugs are separate coverage figures.
- Body/Institution. The 2026 list was recommended by an Expert Committee under the Directorate General of Health Services. The committee included oncologists, medical specialists, hospital experts and government officers.
- Data. Indian Express reported average trade mark-ups of about 170% and instances reaching 700% for non-scheduled anti-cancer medicines. These are reported market findings, not a universal mark-up for every medicine or company.
- Body/Institution. Manufacturers must submit revised prices within seven days and maintain production levels unless the pricing authority permits reduction. Supply continuity is an explicit part of the notification, not an automatic consequence of price reduction.
What should happen
- Create a public dashboard tracking revised prices, stock availability, complaints and hospital compliance for every covered formulation. Price notification without real-time enforcement can leave patients paying old prices or facing non-availability. World Health Organization, Fair Pricing of Medicines report, 2017
- Audit hospital invoices so medicine charges are separated from consultation, administration and infusion charges. Direct hospital sales make medical institutions important distributors and create the risk of shifting costs into opaque service fees. National Pharmaceutical Pricing Authority notification dated October 17, 2026
- Use pooled public procurement and generic or biosimilar competition wherever quality-assured alternatives exist. Competition and large-volume purchasing can lower the underlying acquisition price rather than merely compressing downstream margins. National Health Policy, 2017
- Strengthen financial protection through public insurance, government oncology centres and targeted assistance for high-cost patented therapies. Margin control cannot fully address expensive patented medicines or indirect costs such as travel, diagnostics and repeated hospital visits. Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana
- Review the covered list periodically using clinical need, treatment alternatives, price data and supply-risk assessment. Cancer therapies, patents and market structures change, so a static list may miss new high-cost medicines or create unintended shortages. Expert Committee under the Directorate General of Health Services, 2026
Jargon, demystified
- National Pharmaceutical Pricing Authority (NPPA)
- The government pricing authority that regulates medicine prices and monitors compliance under pharmaceutical price-control rules. It functions under the Department of Pharmaceuticals.
- Trade Margin Rationalisation (TMR)
- A policy that limits the share added by distributors and retailers between the manufacturer and the final buyer. It is different from fixing the manufacturing cost.
- Non-scheduled medicine
- A medicine not included in the scheduled list whose price is not automatically governed by the standard ceiling-price mechanism. Non-scheduled does not mean completely beyond government regulation.
- Maximum Retail Price (MRP)
- The highest printed price at which a medicine may be sold to a consumer, generally shown before or with applicable tax details. The present calculation uses MRP excluding Goods and Services Tax.
- Goods and Services Tax (GST)
- India's indirect tax on the supply of goods and services, added separately where applicable to the calculated medicine price. The 30% margin calculation excludes GST.
- Price to Stockist or Price to Distributor (PTS/PTD)
- The manufacturer's net selling price to the stockist or distributor, used as the base for calculating the regulated price. A margin on MRP is mathematically different from a mark-up on PTS or PTD.
- Drugs (Prices Control) Order, 2013 (DPCO)
- The legal order providing India's framework for controlling prices of specified medicines and permitting public-interest intervention. Paragraph 19 was used for this trade-margin intervention.
Check the term
What does "Trade Margin Rationalisation (TMR)" mean?
Check the term
What does "Drugs (Prices Control) Order, 2013 (DPCO)" mean?